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ABSTRACT 
Aims & Objectives: The present work deals with the modification of controlled release dosage form of poorly water soluble drug 
(Metoclopramide hydrochloride) in order to improve the bioavailability and to control drug release for a longer period of time by 
the aid of solid dispersion.  
Methods: Various binary combination of MET-solid dispersion was prepared with different carriers such as HPβCD, PVP K30 and 
PLX-188 by solvent evaporation technique and then the aqueous solubility, dissolution study and phase solubility study was 
performed. DSC analysis is performed to carry out for metoclopramide loaded solid dispersion, physical mixture & also for pure 
drug to analyze the crystalline and amorphous nature of compounds. 
Results and Discussion:  The saturation solubility of Metoclopramide with various carriers at different pH was performed and 
found that in pH 5.5 (solubility is 5553.2µg/ml), pH 6.8 (3363.3µ/ml), pH 7.4 (1367.3µg/ml) at 37oC. In dissolution study of solid 
dispersion (5:1) of different carriers in DDW, the Cumulative % dissolution is found in the order of PVP K30>PLX-Met>HPβCD-Met 
& in pH 7.4, in the order of PLX-Met>PVP K30>HPβCD-Met. DSC thermogram of Metoclopramide base showed a sharp endothermic 
peak at its melting point (147oC) which exhibits in crystalline form complying with that of Metoclopramide hydrochloride form, 
melting point was found to be 850C.  In the ex-vivo study of several transdermal patches, patch C [SD of MET: HPβCD (1:5)] showed 
the controlled release and permeation of drug.  
Conclusion: Poor solubility of new chemical entities being a well known problem for past few decades despite the imbalance 
between significant research efforts & few successful marketed formulations, the solid dispersion proves to hold a key position 
among all the various formulation strategies to enhance the aqueous solubility & dissolution rate and thereby the bioavailability of  
poorly aqueous solubility of drug. 
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List of abbreviations 
API                                       Active Pharmaceutical Ingredients 
MET                                     Metoclopramide 
M.W.                                    Molecular Weight 
M.P.                                     Melting Point 
HPβCD                                Hydroxypropyl-Beta-Cyclodextrin 
PVP                                      Polyvinyl pyrrolidone 
PLX                                      Poloxamer 
SD                                          Solid Dispersion 
DSC                                        Differential Scanning Calorimetry 
NCE                                        New chemical entities 
KC                                                                  Complexation constant 
∆G                                          Gibbs free energy change 
∆H                                          Enthalpy change 
∆S                                           Entropy change 
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INTRODUCTION 
Drug development process plays an important role in 
achieving scientific success and commercial launching of 
drug product. The study of solubility is of important 
concern to improve dissolution rate, bioavailability of drug 
and to control drug release and to achieve desired 
therapeutic responses for a prolong period of time.Now-a-
days, in drug discovery, the main motto has been to 
produce more and more compounds that exhibit high 
lipophilicity and poor water solubility. Such 
physicochemical characteristics lead to problematic 
biopharmaceutical properties which in turn diminish the 
likelihood success in the clinic. The principle objective of 
dosage form design is to achieve a predictable therapeutic 
response to a drug included in a formulation which is 
capable of large scale manufacture with reproducible 
product quality.Many of new API emerging out of 
throughput and combinatorial screening tools are under 
great challenge owing to their poor aqueous solubility and 
dissolution rate. Morethan 40% NCEs (new chemical 
entities) developed in pharmaceutical industries are 
practically insoluble in water.Therefore drug solubility 
enhancement is major challenge for formulation scientist. 
Various techniques are used for the enhancement of 
solubility of poorly soluble drugs which includes physical & 
chemical modification of drug, particle size reduction, 
crystal engineering, salt formation, solid dispersion, use of 
surfactant, complexation and so forth. 
The rationale of this present investigation was to prepare 
solid dispersion (SD) of Metoclopramide in base form 
(M.W.-299.8) with various carriers to enhance its aqueous 
the solubility by solid dispersion technique and to compare 
the solubility in various types of aqueous media and its use 
in preparation of transdermal film. In this method 
Metoclopramide base and carrier (i.e. HPβCD, Polaxamer 
188 and PVP K-30) were dispersed in the mixture of 
ethanol & dichloromethane to produce a clear solution by 
stirring in a magnetic stirrer at room temperature and 
subsequently upon the removal of solvent, solid powder 
was obtained. The present study includes the 
determination of the solubility of SD products & phase 
solubility study of binary systems with carriers in order to 
investigate the cause of solubilisation& characterization of 
various solid dispersion products. 
Enhancement of solubility of poorly water sloluble drug by 
solid dispersion technique attributed to particle size 
reduction, improved wettability and dispersibility, higher 
porosity, decreased lattice energy, amorphous state 1.  
The dispersion of an active ingredient in an inert 
hydrophilic carrier at solid form prepared by fusion, 
solvent evaporation technique is defined as solid 
dispersion. Solid dispersions (SDs) traditionally have been 
used as an effective method to improve the dissolution 
properties and bioavailability of poorly water-soluble   
drugs 2. Solid dispersion has attracted considerable interest 
as an effective means of improving the dissolution rate and 
the bioavailability. Solid dispersion systems have been 
realized as extremely useful tool in improving the 
dissolution properties of poorly soluble drugs 3. The first 
drug whose rate and extent of absorption was significantly 
enhanced using the solid dispersion technique was 
sulfathiazole 4 
Metoclopramide is chemically 4-amino-5-chloro-N-[2-
(diethylamino) ethyl]-2-methoxybenzamide, an antiemetic 
and gastroprokinetic agent. It is commonly used to treat 
nausea and vomiting to facilitate gastric emptying in 
people with gastroparesis and as a treatment of gastric 
stasis often associated with migraine headache. The 
molecular formula of Metoclopramide is C14H22ClN3O2, 
which corresponds to a molecular weight of 299.8 & its 
melting point is 147oC. Metoclopramide is basically soluble 
in ethanol & practically insoluble in ether. Its aqueous 
solubility is 200mg/L at 25oC.It is absorbed well after oral 
administration but a significant first pass effect in some 
human patients may reduce systemic bioavailability to 
30%. There apparently is a great deal of interpatient 
variation with this effect. Bioavailability after 
intramuscular administration has been measured to be 74-
96%. After oral dosing peak plasma levels generally occur 
within 2 hours. The drug is well distributed in the body and 
enters the CNS. Metoclopramide is only weakly bound to 
13-22% of plasma proteins.Metoclopramide is primarily 
excreted in the urine in humans approximately 20-25%. 
The majority of the rest of the drug is metabolised to 
glucuronidated or sulfated conjugate forms and then 
excreted through urine. Approximately 5% is excreted in 
the faeces. The half life of Metoclopramide in the dog has 
been reported to be approximately 90 minutes.   
Metoclopramide is basically a Dopamine-2 receptor 
antagonist. Metoclopramide exerts its prokinetic effect by 
antagonizing dopamine mediated relaxation effect on 
gastrointestinal smooth muscle. This enhances the 
response of gastrointestinal smooth muscle to cholinergic 
stimulation and thereby leading to an increase of gastric 
emptying into the intestines. It antagonizes D2 dopamine 
receptors in chemoreceptive trigger zone (CTZ) of medulla 
and thereby preventing nausea and vomiting. 
Metoclopramide also decreases reflux into the oesophagus 
by increasing the resting pressure of the lower oesophageal 
sphincter and improves acid clearance from oesophagus by 
increasing amplitude of oesophageal peristaltic 
contractions. A study showed that high dose of 
Metoclopramide antagonizes 5-hydroxytryptamine (5HT) 
receptors in the peripheral nervous system in animals. 
To achieve a desired release and therapeutic response to a 
drug included in the formulation is always preferable. So, 
after enhancing the solubility and dissolution rate of poorly 
soluble drugs, the development of dosage form is often 
necessary to achieve the desired release pattern and 
effective therapeutic response. Therefore, to achieve as 
well as to maintain the drug concentration within the 
therapeutically effective range, the prepared MET base 
solid dispersion was developed as a transdermal drug 
delivery system using controlled release polymer and 3M 
backing layer membrane. Topical & transdermalproducts 
remain key formulation for drugs to the skin for systemic 
action 5. In order to asses permeability of drug through skin 
transdermal patches were formulated by without MET HCl 
drug and polymers, MET base drug and polymers, SD of 
MET:HPβCD and polymers, SD of MET:PVP K30 and 
polymers and SD of MET:PLX-188. 
MATERIALS USED 
Polymers used: 
 Hydroxypropyl-β-cyclodextrin (HPβCD) [Tokyo 
Chemical Industries Co.Ltd.] 
 Polyvinyl pyrolidone  (PVP K-
30)[LobaChemie,Mumbai] 
 Poloxamer-188[Sigma Chemicals] 
 Ethyl cellulose[Sigma Aldrich Chemicals] 
 Hydroxypropyl Methylcellulose or Hypromellose 
(HPMC)[Colorcon Asia Pvt.Ltd,GAO,INDIA] 
Drug used: Metoclopramide HCL (M.P:-147oC, M.W:-299.8 
g/mol) [Yarrow chemicals] 
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Reagent used: 
 Potassium dihydrogen phosphate (Merck specialities 
Pvt. Ltd., Mumbai), 
 Sodium hydroxide (Merck specialities Pvt. Ltd., 
Mumbai),  
 Sodium chloride (Qualikems Fine Chemicals Pvt. Ltd., 
New Delhi). 
Solvent used: 
 Acetone(Quest Chemicals, Kolkata), 
 Methanol(SpectrochemPvt. Ltd.,Mumbai),  
 Dichloromethane (Merck specialities Pvt. 
Ltd.,Mumbai),  
 Ethanol(obtained from the departmental store of 
BCDA college of Pharm. Tech.), 
 Double distilled water (obtained from the lab of 
Pharmaceutical Engineerining of BCDA college of 
Pharm. Tech.), 
 Phosphate buffer pH7.4. 
Plasticizer used: Dibutyl phthalate (Merck specialities Pvt. 
Ltd., Mumbai) 
Backing Layer: Gifted by 3M Drug Delivery, USA. 
APPARATUS 
 Metal applicator: Stain less steel 316, length 9cm, 
breadth 2cm, height 11cm, width of gap for film 
casting 150,250,350,500µ. 
 Franz diffusion cell was fabricated by Remco (local 
glass blower), height, internal diameter, outer 
diameter and volume of receptor cell are 11cm for 
both (receptor cell and donor cell), 2cm (internal 
diameter of donor cell) and 50ml respectively. Both 
ends of donor cell (elongated tube) are open; diameter 
of external opening is 2.5 cm. Receptor cell is jacketed 
externally for water circulation. 
INSTRUMENTS 
 UV-Visible spectrophotometer (ANALAB, UV-180). 
 Water bath (Integrated electrolife system by SUNBIM) 
 Magnetic stirrer (Trason, multispins) and REMI 
(2MLH, magnetic stirrer). 
METHODS 
Conversion of Metoclopramide hydrochloride to 
Metoclopramide base form: 
Metoclopramide is available in hydrochloride form 
(aqueous soluble) in the market. Therefore for sake of the 
research it is converted from hydrochloride form to 
Metoclopramide. 
4gm of Metoclopramide hydrochloride was dispersed in 
the sufficient double distilled water followed by stirring 
until the total amount of drug gets fully dissolved. The 
solution is neutralized by 1M sodium hydroxide solution & 
gradually a precipitate was formed and the precipitate was 
collected by filtration (Whatman filter paper grade 1) and 
the precipitate thus obtained was washed several times 
with double distilled water to remove HCL which was 
produced during precipitation.Thereafter the wet 
precipitate was dried in hot air oven at 50oC. Afterward the 
solid material was cooled up to room temperature (25oC) 
and was treated with acetone in order to make a saturated 
solution and stirred continuously at 50oC. Then the 
solution was allowed to attain room temperature & 
thereafter it was kept in refrigerator and crystal particles 
of Metoclopramide (base form) was formed and collected. 
The material was cooled at room temperature and it was 
weighed and its melting point was determined. 
Preparation of Calibration Curve: 
In order to prepare the calibration curve, 10mg of drug 
(metoclopramide base) was actually weighed and dissolved 
in known volume of methanol (~3ml) and finally the rest of 
the volume was adjusted with aqueous phase (DDW, 
Phosphate buffer pH 7.4) up to 100ml. A series of dilution 
were made form stock solution (2-20µg/ml concentration) 
for each buffers and assayed under UV-spectrophotometer 
(ANALAB and model of UV-180) at the wave length of 
272nm and the average absorbance data of three 
observations were plotted against dilutions.  The linear 
curve for phosphate buffer pH7.4, DDW, Phosphate buffer 
pH 6.8 &pH 1.2 buffer showed (R2=0.999, 
Y=0.049x+0.018),(R2=0.999, Y=0.049x+0.009),(R2=0.999, 
Y=0.044x+0.003) & (R2=0.9997, Y=0.0324x+0.0077) 
respectively. Thus the unknown concentration of 
Metoclopramide is estimated. 
Preparation of solid dispersion (SD) by solvent 
evaporation technique: 
Solid dispersion prepared from hydrophilic polymers using 
the solvent evaporation technique is effective in improving 
drug dissolution. Solvent evaporation method was carried 
out by dispersing a physical mixture of drug and polymer 
at certain ratio in a common solvent and then it was 
evaporated until a transparent solvent free thin layer of 
mass was obtained. Then the film was dried till constant 
weight at 50oC 6.   
Characterisation of solid dispersion formulation: 
Characterization of solid dispersion was performed by the 
instrumental analysis like Differential Scanning 
Calorimetry (DSC) analysis. 
Differential scanning calorimetry(DSC) analysis: 
DSC analysis is mainly carried out for metoclopramide 
loaded solid dispersion, physical mixture & also for pure 
drug to analyze the crystallinity and amorphous nature of 
compounds. The analysis was carried out in Pyri’s diamond 
TG/DTA; P, Perkins Elmer Instruments) supported by a 
thermal analyzer. Under the nitrogen flow of 150 ml/min, 
approximately 10mg of sample (Metoclopramide base, 
polymer substances and solid dispersions) was placed in a 
sealed aluminium pan and heated at scanning rate of 
10oC/min over the temperature of 30oC-300OC. 
Determination of aqueous solubility of drug: 
Aqueous solubility study was performed by taking excess 
amount of metoclopramide in an aqueous phase 
(phosphorous buffer pH 7.4, DDW, phosphate buffer pH 6.8 
and pH 5.5 buffers) and shaken at 37oC, 40oC, 45oC 
respectively and observed after 24 hr to obtain solubility. 
Dissolution Study: 
Dissolution study of Metoclopramide was performed in 
(Yarrow Chem. Products, Phosphorous buffer pH 7.4 with 
0.9% NaCl, USP rotating paddle II type) dissolution 
apparatus under sink condition at 37±0.5oC and 50 rpm. A 
sample of solid dispersion equivalent to 10mg of 
metoclopramide was used in each test. Samples were 
withdrawn at distinct time intervals and absorbance was 
absorbed at λmax of 272nm using UV-visible 
spectrophotometer. 
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Phase solubility analysis: 
The phase solubility study is carried out to determine 
binding/complexation constant (Kc) of polymer –drug 
complexes. These complexes effectively modify the 
solubility characteristics of drug.  Phase solubility study 
was performed by dissolving known amount of polymers 
with increasing amount to each of series of test tubes 
containing aqueous phase (phosphate buffer pH 7.4, DDW). 
Thereafter excess amount of drug was added to each of the 
tube shaken for 24 hrs at 25o, 37o, 40o& 45o C respectively. 
After 24 hr very slight quantity of insoluble material was 
observed at the bottom of each test tube and then the 
content of each test tube was filtered and the filtrate was 
collected and its absorbance was recorded and Ka was 
calculated. 
Fabrication of transdermal patch: 
Patch was fabricated with the prepared formulations 
containing the polymers ethyl cellulose, HPMC, PVP K30 at 
different composition in addition with known amount of 
dibutyl phthalate as plasticizer and liquid blend as cast on 
the 3M backing layer membrane by a metal applicator. The 
different Patchesare: 
 Patch A: HPMC(50mg)+EC(100mg)+PVPK30 (100mg) 
 Patch B: HPMC(50mg)+EC(100mg)+PVPK30 
(100mg)+MET base pure drug(100mg) 
 Patch C: HPMC(50mg)+EC(100mg)+PVPK30 
(100mg)+ SD of MET-HPβCD(1:5)[equivalent to 
100mg] 
 Patch D: HPMC(50mg)+EC(100mg)+PVPK30 
(100mg)+SD of MET-PLX-188(1:5)[equivalent to 
100mg] 
 Patch E: HPMC(50mg)+EC(100mg)+PVPK30 
(100mg)+SD of MET-PVP K30 (1:5) 
 Patch F: HPMC(50mg)+EC(100mg)+PVPK30 
(100mg)+MET HCl (100mg drug) 
Ex-vivo permeation study: 
Ex-vivo permeation study was done by using excised ear 
part of pig followed by the removal of external debris. After 
cleaning a part of ear it was mounted between the donor 
and receptor compartment of Franz diffusion cell (gas 
apparatus). The receptor portion contains aqueous phase 
(phosphate buffer pH 7.4 with 0.9% NaCl). Permeation 
study was carried out using pure drug and solid dispersion 
formulations in the donor cells which is in contact with the 
dorsal part of ear skin. Concentration of the drug (1mg/ml 
and 5mg/ml)/ solid dispersion was maintained with 
solvent (ethyl alcohol & phosphate buffer pH 7.4 with 0.9% 
NaCl) in the donor cells. Samples of permeate was collected 
at the intervals of 30 minutes at a constant temperature 
37oC and replaced immediately by equal amount of fresh 
aqueous phase. Then the collected samples are analyzed in 
spectrophotometer at 272nm. 
 
In vitro diffusion study: 
In vitro diffusion study was carried out by using Franz 
diffusion cell. The Franz diffusion cell has a receptor 
compartment of approximately 50ml and effective surface 
area of diffusion/ permeation was 3.14cm2. The study was 
conducted in two steps: 
i. At first the diffusion of the drug from the transdermal 
patch was studied. Patch was attached between donor 
and receptor cell and samples were withdrawn from 
liquid (phosphate buffer pH 7.4) of receptor cell at 
intervals and drug amount present in the samples was 
determined by observing the absorbance. 
ii. Secondly, diffusion of drug and simultaneous 
permeation of drug through the porcine ear skin was 
studied. The ear portion of pig was duly excised and 
external debris was removed by treating with 
phosphate buffer pH 7.4 for half an hour. Then excised 
skin was placed in between donor and receptor 
compartment and a weighed extent of transdermal 
patch was fixed on the dorsal side of the skin. The 
receptor cell was filled up with phosphate buffer pH 
7.4 and its content was stirred by a magnetic bar 
placed inside the cell. Temperature of receptor cell 
was maintained at 37±0.5oC by circulating the water 
trough the external jacketed path. Water was supplied 
by a constant temperature water bath.Franz diffusion 
cell was placed on a multi cell magnetic stirrer. 
Samples were withdrawn at intervals and replaced by 
equal amount of fresh buffer and the samples as 
collected were analyzed in a spectrophotometer at 
wave length of 272nm. 
Determination drug content (%) of film: 
Drug content analysis was evaluated by taking 2ml of 
methanol followed by addition of 1 square centimetre of 
different patches and stirred with a magnetic stirrer. Then 
DDW was slowly added & diluted up to 100ml in a 
volumetric flask. Then the solution was filtered and the 
content of drug was determined by UV Spectrophotometer. 
Blank solution was made by the blank patch (patches 
without drug).   
RESULTS& DISCUSSION 
 Determination of λmax of  Metoclopramide: 
λmax of Metoclopromide base was determined first by 
scanning the solution of Metoclopromide in UV 
spectrophotometer. λmax of Metoclopromide was found to 
be 272 nm. 
 Preparation of standard curve: 
The standard curve was prepared by plotting absorbance 
against concentration of individual analyst. The calibration 
graph was found to be a linear in concentration range of 2-
20µg/ml in double distilled water (DDW) at pH 7.4, pH 6.8 
and pH 1.2.
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Table 1: Absorbance of metoclopramide at 272nm for different concentrations in DDW & in pH 7.4 
Absorbance in 
DDW 
Serial no. Concentration (µg/ml) Absorbance at 272nm 
1. 2 0.113 
2. 4 0.2112 
3 6 0.3056 
4. 8 0.411 
5. 10 0.5112 
6. 12 0.615 
7. 14 0.7142 
8. 16 0.8174 
9. 18 0.9032 
10. 20 0.9964 
Absorbance in 
pH 7.4 
Serial no. Concentration (µg/ml) Absorbance at 272nm 
1. 2 0.112 
2. 4 0.2138 
3 6 0.3142 
4. 8 0.4016 
5. 10 0.525 
6. 12 0.6106 
7. 14 0.7078 
8. 16 0.7992 
9. 18 0.9014 
10. 20 0.995 
 
 
Figure 1: Standard curve in DDW & in pH 7.4 
Table 2: Absorbance of Metoclopramide at 272nm for different concentrations in pH 6.8 & in pH 1.2 
y = 0.0496x + 0.0143 
R² = 0.9996 
y = 0.0491x + 0.0184 
R² = 0.9995 
0 
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0.8 
1 
1.2 
0 5 10 15 20 25 
Absorbance in DDW Absorbance in pH 7.4 
Linear (Absorbance in DDW) Linear (Absorbance in pH 7.4) 
Absorbance in 
pH 6.8 
Serial no. Concentration (µg/ml) Absorbance at 272nm 
1. 2 0.0924 
2. 4 0.185 
3 6 0.2728 
4. 8 0.3638 
5. 10 0.4466 
6. 12 0.5462 
7. 14 0.635 
8. 16 0.7232 
9. 18 0.82144 
10. 20 0.8926 
Absorbance in 
pH 1.2 
Serial no. Concentration (µg/ml) Absorbance at 272nm 
1. 2 0.0722 
2. 4 0.137 
3 6 0.2066 
4. 8 0.265 
5. 10 0.3298 
6. 12 0.4006 
7. 14 0.4548 
8. 16 0.5236 
9. 18 0.593 
10. 20 0.6584 
 Mukhopadhyay et al                                                                                      Journal of Drug Delivery & Therapeutics. 2018; 8(6):183-191 
ISSN: 2250-1177                                                                                 [188]                                                                                  CODEN (USA): JDDTAO 
 
Figure 2: Standard curve in pH 6.8 & pH 1.2 
Table 3: Study of aqueous solubility of binary solid dispersion of Metoclopramide with various carriers at 37oC 
 
 
Figure 3: Effect of carrier (HPβCD) drug ratio of SD on 
the solubility of MET. In DDW 
 
Figure 4: Effect of carrier (HPβCD) drug ratio of SD on 
the solubility of MET. In pH 7.4 
 Study of aqueous solubility of solid dispersion at 
37oC 
In the above Fig3 & Fig4, Table3, the saturation solubility 
of Metoclopramide with various carriers was shown. 
Metoclopramide is sparingly soluble (191.83µg/ml) in 
double distilled water (DDW). Its aqueous solubility 
increases linearly keeping the drug amount fixed when 
fraction of carrier substance (HPβCD) in solid dispersion of 
drug is increased. Solubility of pure Metoclopramide 
increases in acidic pH. In pH 5.5 (solubility is 
5553.2µg/ml), pH6.8 (3363.3µ/ml), pH 7.4 (1367.3µg/ml) 
which are higher than that of the solubility in DDW 
(191.8µg/ml) at 37oC.  After comparing various data of 
solubility it is observed that the solubility of drug in pH 5.5 
is 28.95(=5553.2/191.8) times greater than that of pure 
drug in DDW in samples without any carrier substances. 
In the medium of DDW, enhancement of solubility of SD-
HPβCD drug (5:1) is 4.55 times more than that of pure 
drug. In acidic medium (pH 5.5), enhancement is very high 
(~97 and ~27 times) in comparison with that of the pure 
drug in DDW and SD in DDW respectively when ratio is 
10:1. 
In case of Poloxamer effect (50.67 times) was higher. In 
case of PVP K-30 drug solubility enhancement in DDW was 
lesser in comparison with that of HPβCD. Its solubility 
increases with the enhancement of amount of carrier in SD. 
 Dissolution study of solid dispersion: 
Dissolution of solid dispersion (5:1) in two medium was 
performed. In DDW the Cumulative % dissolution is found 
in the order of PVP K30>PLX-Met>HPβCD-Met & in pH 7.4 
it is in the order of PLX-Met>PVP K30>HPβCD-
Met.Dissolution study of SD of HPβCD: MET (5:1) in four 
different media is performed and observed that the 
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dissolution was increased by the increasing of buffer pH. The order is pH5.5> pH6.8> DDW> pH 7. 
 
 
Figure 5: Effect of pH on MET: HPβCD-SD (1:5) of different dissolution media on rate of dissolution. 
 
 Drug content of solid dispersion products: 
Various binary combination of MET-solid dispersion was 
prepared with different carriers such as HPβCD, PVP 
K30and PLX-188 by solvent evaporation technique. In the 
table 4 the data of drug content were shown.HBβCD have 
the ability to enhance the solubility by the complex 
formation 7. Hydroxy propyl –β-cyclodextrin is a hydroxyl 
alkyl derivative of βcd& has a wide application increasing 
the field of drug solubility because of its inclusion ability 
along with its high water solubility 8. In case of water 
soluble polymers PVP K30 and PLX-188, the solubility of 
MET was enhanced with increasing amount of carrier 
substances in each medium. 
 
Table 4: Drug content of MET: HPβCD/PVP K30/PLX (1:5) solid dispersion 
Polymer Absorbance in media DDW 
[Y=0.049x+0.009] 
Drug (1µg) present in SD 
products(µg) 
HPβCD 0.775 6.473 
PVP K30 0.745 6.658 
PLX-188 0.860 5.7579 
 
 Phase solubility study: 
The study of Phase solubility was performed with three 
different carriers at different temperature and from the 
slope and the intercept of solubility curves the binding 
constants & thermodynamic parameters such as change of 
free energy (∆G), change of enthalpy (∆H) and change of 
entropy (∆S) was calculated. Free energy change of these 
binary combinations was found negative which indicates 
spontaneous solubilisation. Free energy change varies 
from ~-9 to 15 KJ/mol which suggests that the drug may 
bind with the carrier molecules which are held by weak 
physical forces like Vander Waals force, Hydrogen bonding 
and some hydrophobic forces. 
The effect of temperature (298-318K) on Kc in pH 7.4 was 
much prominent in each binding in comparison with that 
of pH 7.4 and DDW.With the rise of temperature the 
mobility of ionic species of MET in acidic pH increases 
which in turn, possibly inhibits complex formation with the 
carriers. At the higher temperature, the intrinsic solubility 
of the drug increased while the stability constants are 
found low. Stability constant is lowered with the decreased 
of pH in (pH 7.4>pH 5.5) each system. The degree of 
dissociation of MET increases with the decrease of pH so 
the Kc value decreases in acidic pH due to less interaction 
between ligand and guest molecules9. 
The entropy change (∆S) was found negative in pH 5.5 & 
positive in higher pH. Negative entropy change and low Kc 
values in acidic pH 5.5 may be explained as ligand 
molecules are more ionized at pH 5.5 and water molecules 
are comparatively more ordered.  
Higher Kc values for the MET-PVP K30 AND CV-PLX 407 
systems are observed in comparison with that of the 
systems with MET-HPβCD and as a result MET-PVPK30 & 
MET-PLX 180 system showed a low solubility than that of 
other carrier. 
 DSC Analysis: 
Differential scanning calorimetry confirms about 
crystalline or amorphous nature of compounds. DSC 
thermogram of Metoclopramide base showed a sharp 
endothermic peak at its melting point (147oC) which 
exhibits in crystalline form complying with that of 
Metoclopramide hydrochloride form, melting point was 
found to be 850C. DSC thermogram of physical mixture 
(drug: carrier= Metoclopramide base: HPβCD=1:5) had 
showed a small endothermic peak similar to that of 
Metoclopramide base. Thermograms of solid dispersion 
(drug:HPβCD =1:5) revealed disappearance of 
endothermic peak of Metoclopramide base corresponding 
to its melting point due to its uniform homogeneous 
dispersion within the drug and carrier, amorphization by 
overcoming crystal lattice energy and subsequent binding 
by hydrogen bond within the amorphous carrier HPβCD. 
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                              Figure 6: DSC of MET base.                            Figure 7: DSC hysical misture of MET- HPβCD. 
 
Table 5: Binding constants & thermodynamic function for the interaction of MET base with various carriers in 
different pH mediums at different temperatures 
Carriers Temp. 
In 
Kelvin 
Medium, DDW Medium, pH 7.4 Medium, pH 5.5 
Ka(M-1) ∆G,∆H,∆S 
(298-318)K 
Ka(M-1) ∆G,∆H,∆S 
(298-318)K 
Ka(M-1) ∆G,∆H,∆S 
(298-318)K 
PVP-K30 298 95.71968 ∆G=-11.301 
∆H=26.600 
∆S=0.127 
    
310 145.0439 ∆G=-12.331 
∆H=237.479 
∆S=0.838 
    
313 350.7873 ∆G=-14.519     
HPβCD 298 81.57048 ∆G=-10.905 
∆H=-10.391 
∆S=0.0017 
73.9589 ∆G=-10.6623 
∆H=-12.196 
∆S=-0.0052 
61.35846 ∆G=-10.1995 
∆H=-19.0854 
∆S=-0.0298 
 
 
 
310 69.34625 ∆G=-10.5027 
∆H=-7.884 
∆S=0.0087 
61.1273 ∆G=-10.1902 
∆H=-5.8992 
∆S=0.014399 
45.5377 ∆G=-9.4607 
∆H=-9.8532 
∆S=-0.00132 
 
313 
67.34263 
 
∆G=-10.430 
∆H=-6.4624 
∆S=0.0133 
 
59.8008 
∆G=-10.1358 
∆H=-10.5123 
∆S=-0.00126 
43.8993 
 
∆G=-9.3699 
 
318 64.76378 ∆G=-10.333 56.1206 ∆G=-9.97483 41.6846  
PLX-188 298 444.9036 ∆G=-15.108 
∆H=-5.3565 
∆S=0.0327 
    
310 409.185 ∆G=-14.900 
∆H=-42.277 
∆S=-0.0918 
    
313 349.6546 ∆G=-14.511 
∆H=-77.528 
∆S=-0.2114 
    
 
 Mukhopadhyay et al                                                                                      Journal of Drug Delivery & Therapeutics. 2018; 8(6):183-191 
ISSN: 2250-1177                                                                                 [191]                                                                                  CODEN (USA): JDDTAO 
 
Figure 8: DSC of SD of MET- HPβCD(1:5) 
 Ex-vivo Permeation Study of Patches: 
Table 6: Ex-vivo permeation study of MET pure drug and its solid dispersions. 
SL.No. Permeation Experiment Code Average slope 
(µg/min) 
SL.No. Permeation Experiment 
Code 
Average slope 
(µg/min) 
1. A1 (1mg, ET), Pure drug 4.316 1. A3(1mg,PBS),Pure drug 3.443 
2. B2 (5mg, ET), Pure drug 3.453 2. B3(5mg,PBS),Pure drug 4.143 
3. C1 (1mg, ET), HPβCD-SD 4.506 3. C3(1mg,PBS),HPβCD-SD 2.120 
4. D1 (5mg, ET), HPβCD-SD 5.073 4. D3(5mg,PBS), HPβCD-SD 5.107 
5. E1 (1mg,ET),PLX-SD 3.923 5. E3(1mg,PBS),PLX-SD 1.630 
6. F1 (5mg, ET), PLX-SD 5.976 6. F3(5mg,PBS),PLX-SD 5.930 
7. G1 (1mg,ET), PVP K30-SD 5.113 7. G3(1mg,PBS),PVP K30-SD 2.935 
8. H1 (5mg,ET), PVP K30-SD 5.450 8. H3(5mg,PBS),PVP K30-SD 4.718 
[Drug /SD dissolved in ET(ethanol 96%), PBS-Phosphate buffer pH 7.4, 1 mg-1mg/ml, 5 mg-5mg/ml] 
 
The ex-vivo study of transdermal patch C [SD of MET: 
HPβCD (1:5)] showed the controlled release and 
permeation. And SD of MET: PLX-188 (1:5) [Patch D] was 
permeating slowly through the skin, Patch B & Patch E 
showed  higher permeation but not controlled release 
permeation at a time. 
CONCLUSION 
Poor solubility of new chemical entities is a well known 
problem for past few decades.Despite the imbalance 
between significant research efforts & few successful 
marketed formulations, the solid dispersion proves tobe a 
key position among all the various formulation strategies 
to enhance the aqueous solubility & dissolution rate and 
thereby the bioavailability of drug. The solid dispersion of 
drug prepared with HPβCD by solvent evaporation 
technique showed a better dissolution rate in pH 7.4 and 
solubility 1367.3µg/ml in pH 7.4. 
The dissolution rate & solubility of the prepared solid 
dispersions were improved when compared with that of 
pure drug due to conversion of drug from crystalline to 
amorphous nature and formation of complexation between 
drug and hydrophilic carriers. The result of experiment 
reveals that the preparation of MET solid dispersion with 
HPβCD by solvent evaporation method is promising 
approach to improve the solubility and dissolution rate of 
MET base. 
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